
ABSTRACT: Levamisole-induced cutaneous vasculitis represents a distinctive form of drug-induced vasculopathy that has emerged as a significant clinical challenge, particularly since the widespread use of levamisole as a cocaine adulterant. This review provides a concise overview of this entity, with a specific focus on its epidemiology, pathophysiology, clinical presentation, histopathological features, immunological profile, and therapeutic management. Key clinical features include stellate or retiform purpura with a predilection for the ears and extremities, characteristic serological findings with mixed antineutrophil cytoplasmic antibody positivity, and distinctive histopathological patterns showing both leukocytoclastic vasculitis and thrombotic vasculopathy. Recognition of this entity is essential for accurate diagnosis and appropriate management, as its treatment differs substantially from that of primary antineutrophil cytoplasmic antibody-associated vasculitides. This review synthesizes current evidence to provide clinicians and pathologists with a practical overview of this increasingly recognized condition.
INTRODUCTION In situ onycholemmal carcinoma, also termed atypical or malignant onychopapilloma, is an exceptionally rare nail unit neoplasm that is clinically difficult to distinguish from its benign counterpart. We report the youngest documented case of this entity and the first occurring in a patient with hereditary retinoblastoma due to a germline RB1 mutation. CASE PRESENTATION A 20-year-old woman with hereditary retinoblastoma presented with a 2-year history of progressive longitudinal erythronychia of the left second fingernail. Longitudinal excisional biopsy revealed an atypical epithelial proliferation with onycholemmal keratinization, diffuse Ki-67 expression, and negative p16 staining, consistent with in situ onycholemmal carcinoma. The lesion was successfully treated with Mohs micrographic surgery, and no recurrence was observed after 6 months. CONCLUSION This case expands the clinical spectrum of in situ onycholemmal carcinoma by demonstrating its occurrence in a young patient with a germline RB1 pathogenic variant. The findings raise the possibility of a role for RB pathway dysregulation in tumor pathogenesis and underscore the importance of maintaining a low threshold for biopsy of evolving longitudinal erythronychia, particularly in patients with inherited cancer predisposition syndromes.
ABSTRACT Acquired elastotic hemangioma is an uncommon benign cutaneous vascular proliferation first described in 2002 that typically presents as a solitary erythematous plaque arising on chronically sun-exposed skin. Histologically, it is characterized by a superficial, band-like, horizontally oriented capillary proliferation associated with marked solar elastosis. In contrast, vulvar elastosis develops in an anatomical site protected from ultraviolet radiation and has been linked to aging, hormonal changes, and inflammatory or reparative processes.In this article, we report the lesion of a 67-year-old woman with vulvar lichen sclerosus who presented with a palpable 1-cm nodule involving the left labium majus. Her medical history was notable for an undifferentiated ovarian carcinoma diagnosed 19 years earlier, treated with chemotherapy and currently in remission. Histopathological examination revealed superficial features of lichen sclerosus and, within the underlying dermis, a nodular accumulation of thick, irregular elastic fibers intermingled with numerous mature blood vessels lacking endothelial atypia.In conclusion, a prominent vascular component may represent a feature of nodular vulvar elastosis and should not necessarily be interpreted as evidence of a primary vascular neoplasm.
Abstract: Blue nevus–related lesions span a broad histopathological continuum, from benign common and cellular blue nevi to atypical cellular blue nevus and malignant blue nevus. The intermediate and malignant forms are rare, diagnostically nonstandardized and may closely mimic metastatic melanoma. We retrospectively reviewed 3 consecutive patients with rare blue nevus variants managed at a tertiary referral center between 2019 and 2025. Cases were eligible if they were histopathologically confirmed, showed diagnostic uncertainty or had initially been interpreted as metastatic melanoma, and had follow-up sufficient to assess clinical outcome. All slides were independently reviewed by 2 dermatopathologists, and 1 case additionally underwent external expert consultation and comparative genomic hybridization. Patient 1 had axillary capsular blue nevi misread as nodal metastases, leading to unnecessary completion dissection. Patient 2 developed malignant blue nevus within a plaque-type blue nevus, with simultaneous benign capsular and vascular-adventitial blue nevus deposits. Patient 3 had amelanotic cellular blue nevus–like melanoma mimicking dermatofibroma, with negative comparative genomic hybridization despite a suspicious subcapsular sentinel-node focus. Integrated clinical, dermatopathological, immunomorphological, and molecular assessment is essential to avoid both under- and over-treatment.